Estrogen may contribute to the development of Raynaud’s phenomenon in women, according to a study examining the relationship between palm blood ... Read more
The U.S. Food and Drug Administration (FDA) has granted Cytori Therapeutics Small Business status designation for fiscal year 2017, meaning that the company ... Read more
Recognizing the signs and early identification of artifactual hypoglycemia in patients with Raynaud’s phenomenon and/or systemic sclerosis is critical to prevent ... Read more
A case report of severe Raynaud’s phenomenon in a black-African woman illustrates the difficulties clinicians still face for diagnosis and management. ... Read more
Raynaud’s symptoms ceased in a woman after treatment with hydroxycarbamide returned her platelet count to normal, according to a case study published in ... Read more
Cytori Therapeutics will expand the development of its ECCS-50 scleroderma treatment to include secondary Raynaud’s phenomenon (RP), under the brand Habeo ... Read more
A randomized, controlled clinical trial was performed to evaluate the effects of acupressure on Raynaud’s phenomenon (RP), however, no significant impact ... Read more
Revlimid (lenalidomide) was found to effectively treat skin manifestations in adolescents with systemic lupus erythematosus, including Raynaud’s phenomenon. The study, “Lenalidomide ... Read more
Patients with both primary and secondary Raynaud’s phenomenon have an abnormally low blood penetration in the heart tissue, which likely explains ... Read more
Corbus Pharmaceuticals is starting a one-year, open-label extension study for the ongoing Phase 2 clinical trial evaluating the effect of Resunab in ... Read more